

INTERNATIONAL ENCYCLOPEDIA
OF PHARMACOLOGY & THERAPEUTICS
Section 108

**Hepatic
Cytochrome
P-450
Monooxygenase
System**

Editors:
JOHN B. SCHENKMAN
and
DAVID KUPFER

PERGAMON PRESS

INTERNATIONAL ENCYCLOPEDIA OF
PHARMACOLOGY AND THERAPEUTICS

Section 108

HEPATIC CYTOCHROME P-450 MONOOXYGENASE SYSTEM

SECTION EDITORS

JOHN B. SCHENKMAN

*Department of Pharmacology,
University of Connecticut Health Center, Farmington, CT 06032, USA*

and

DAVID KUPFER

*Worcester Foundation for Experimental Biology,
Shrewsbury, MASS 01545, USA*



PERGAMON PRESS

OXFORD · NEW YORK · TORONTO · SYDNEY · PARIS · FRANKFURT

EDITORIAL BOARD

| | |
|--------------------------------------|------------------------------------|
| D. BOVET, <i>Rome</i> | G. B. KOELLE, <i>Philadelphia</i> |
| W. C. BOWMAN, <i>Glasgow</i> | P. LECHAT, <i>Paris</i> |
| A. M. BRECKENRIDGE, <i>Liverpool</i> | H. RASKOVA, <i>Prague</i> |
| A. S. V. BURGEN, <i>London</i> | A. C. SARTORELLI, <i>New Haven</i> |
| J. CHEYMOL, <i>Paris</i> | V. V. ZAKUSOV, <i>Moscow</i> |

Some Recent and Forthcoming Volumes

- 70 LEVINE
The Chelation of Heavy Metals
- 100 GILL
Pharmacology of Adrenal Cortical Hormones
- 101 HERSHAM and BRAY
The Thyroid
- 102 ZBENDEN and GROSS
Pharmacological Methods in Toxicology
- 103 SARIN and GALLO
Inhibitors of DNA and RNA Polymerases
- 104 WIDDICOMBE
Respiratory Pharmacology
- 105 SZEKERES
Pharmacology of Antiarrhythmic Agents
- 106 CHAUDHURY
Pharmacology of Estrogens
- 107 ERECINSKA and WILSON
Inhibitors of Mitochondrial Functions
- 108 SCHENKMAN and KUPFER
Hepatic Cytochrome P-450 Monooxygenase system

NOTICE TO READERS

Dear Reader

If your library is not already a standing order customer or subscriber to this series, may we recommend that you place a standing or subscription order to receive immediately upon publication all new issues and volumes published in this valuable series. Should you find that these volumes no longer serve your needs your order can be cancelled at any time without notice.

The Editors and the Publisher will be glad to receive suggestions or outlines of suitable titles, reviews or symposia for consideration for rapid publication in this series.

Robert Maxwell
Publisher at Pergamon Press

PREFACE

SINCE its discovery in 1958 as a carbon monoxide-binding pigment in liver microsomes, the number of scientific papers published yearly on studies directly related to this hemoprotein have increased almost logarithmically. This great rate of interest has been, in part, due to the excitement generated by the opening of a new field as well as the great energy of the fairly young group of investigators involved.

From its detection in 1958, recognition as a hemoprotein in 1962, and determination of function in 1963, to its solubilization and reconstitution in 1968 was but a short ten years. Even so, the pace has increased to the point where attempts to compile a book on the enzyme system have been thwarted by the speed of obsolescence of reviews.

It has been our purpose to provide both a historical and prospective view of selected areas of the hepatic microsomal enzyme system, picking the liver as a tissue with which we are both familiar and since much of the advances in the field have been with this enzyme system. Enough differences exist between the cytochrome P-450 enzyme systems of microorganisms, mitochondria and other tissue and species as to make an all-embracing text an impossible task. Perhaps our omissions will encourage other would-be authors to fill the void.

Our goal was to develop an in-depth coverage of each component of the enzyme system and of its functions, but also to provide enough background and history to be an aid to the student or investigator newly entering the field. In soliciting material every attempt was made to obtain leading investigators in the field to provide chapters on their areas of expertise. Considerable efforts were also made to include contributions from younger investigators whose studies have begun to make impact on the field.

Today studies on the mixed function oxidase are carried out by investigators in many fields, including anatomy (histology), bacteriology, biochemistry, biology, biophysics, chemistry, environmental sciences, medicine, pharmacy, pharmacology, therapeutics and toxicology. Alphabetically, with careful searching we could probably find other fields in which cytochrome P-450 has generated excitement. Hopefully, our efforts will prove a benefit in these fields, by providing a ready source of information.

JOHN B. SCHENKMAN

and

DAVID KUPFER

19 May 1980

LIST OF CONTRIBUTORS

- WAYNE L. BACKES**
Department of Pharmacology, University of Connecticut Health Center, Farmington, Connecticut 06032, USA.
- INGEMAR BJÖRKHEM**
Department of Clinical Chemistry, Karolinska Institutet, Huddinge University Hospital, S-141 86 Huddinge, Sweden.
- EDWARD BRESNICK**
Department of Biochemistry, College of Medicine, The University of Vermont, Burlington, Vermont 05401, USA.
- M. DANNY BURKE**
Department of Pharmacology, Marischal College, University of Aberdeen, Aberdeen, AB9 1AS, UK.
- WILLIAM J. CANADY**
Department of Biochemistry, West Virginia University Medical Center, Morgantown, West Virginia 26506, USA.
- MOTT D. CANNON**
Harrison Department of Surgical Research, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA.
- CHARLES E. CASTRO**
Nematology Department, University of California, Riverside, Riverside, California 92521, USA.
- DOMINICK L. CINTI**
Department of Pharmacology, University of Connecticut Health Center, Farmington, Connecticut 06032, USA.
- DAVID Y. COOPER**
Harrison Department of Surgical Research, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA.
- GUSTAV DALLNER**
Department of Biochemistry, Arrhenius Laboratory, Fack, S-104 05 Stockholm, Sweden.
- FRANCESCO DEMATTEIS**
MRC Toxicology Unit, Medical Research Council Laboratory, Woodmansterne Road, Carshalton, Surrey SM5 4EF.
- HELMUT DENK**
Division of Gastroenterologic Pathology, Department of Pathology, University of Vienna, School of Medicine, Spitalgasse-4, A-1090 Vienna, Austria.
- JOSEPH W. DE PIERRE**
Department of Biochemistry, Arrhenius Laboratory, Fack, S-104 05 Stockholm, Sweden.
- JOHN D. DIGNAM**
Department of Biochemistry and Molecular Biology, University of Texas, Health Science Center at Houston, Houston, Texas 77025, USA.
- LENNART C. ERIKSSON**
Department of Pathology, Hudding University Hospital, Karolinska Institutet, Stockholm, Sweden.
- MICHAEL R. FRANKLIN**
Department of Biopharmaceutical Sciences and Pharmacology, Colleges of Pharmacy and Medicine, University of Utah, Salt Lake City, Utah, 84112, USA.
- E. FURUYA**
Department of Biochemistry, School of Medicine, Osaka University, 33 Joanncho, Kitaku, Osaka, Japan.
- JOHN E. GANDER**
Department of Biochemistry, University of Minnesota, College of Biological Sciences, St. Paul, Minnesota 55108, USA.
- HARRY V. GELBOIN**
Chemistry Branch, National Cancer Institute, NIH, Bethesda, Maryland 20014, USA.
- F. PETER GUENGERICH**
Department of Biochemistry, Center of Environmental Toxicology, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232, USA.
- JAMES GUM**
Department of Biochemistry and Molecular Biology, University of Texas, Health Science Center at Houston, Houston, Texas 77025, USA.
- BUNJI HAGIHARA**
Department of Biochemistry, School of Medicine, Osaka University, 33 Joanncho, Kitaku, Osaka, Japan.
- JORDAN L. HOLTZMAN**
Veterans Administration Hospital, Minneapolis, Minnesota 55417, USA.
- YOSHIYAKI ICHIKAWA**
Department of Biochemistry, School of Medicine, Osaka University, 33 Joanncho, Kitaku, Osaka, Japan.
- INGELA JANSSON**
Department of Pharmacology, University of Connecticut Health Center, Farmington, Connecticut 06032, USA.
- RYUICHI KATO**
Department of Pharmacology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160, Japan.
- DAVID KUPFER**
Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545, USA.
- ANTHONY Y. H. LU**
Merck, Sharp & Dohme, Inc., Research Laboratories, Rahway, New Jersey 07065, USA.
- GILBERT J. MANNERING**
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.
- BETTIE SUE MASTERS**
Department of Biochemistry, Southwestern Medical School, The University of Texas, Health Sciences Center, Dallas, Texas 75235, USA.
- DANIEL W. NEBERT**
Developmental Pharmacology Branch, NICHD, NIH, Bethesda, Maryland 20205, USA.
- KARL J. NETTER**
Department of Pharmacology, School of Medicine, University of Marburg, Lahneberge, D-3550 Marburg/Lahn, West Germany.
- BEATRICE G. NOVACK**
Harrison Department of Surgical Research, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA.
- PETER J. O'BRIEN**
Department of Biochemistry, Memorial University of Newfoundland, St. John's, Newfoundland, A1C 5S7, Canada.
- RICHARD T. OKITA**
Department of Biochemistry, The University of Texas, Southwestern Medical School, Dallas, Texas 75235, USA.

- TSUNEO OMURA
Department of Biology, Kyushu University,
Faculty of Science, Fukuoka 812, Japan.
- STEN ORRENIUS
Department of Forensic Medicine, Karolinska
Institutet, S-104 01 Stockholm 60 Sweden.
- NOZOMU OSHINO
Research and Development Department, Nikon
Schering K.K., 2-6-64 Nishimiyahara,
Yodogawa-Ku, Osaka 532 Japan.
- GARTH POWIS
Department of Oncology, Mayo Clinic, Roches-
ter, Minnesota 55901, USA.
- HERBERT REMMER
University of Tübingen, Institute of Toxicology,
7400 Tübingen 1, Germany.
- OTTO ROSENTHAL (deceased)
Harrison Department of Surgical Research, Uni-
versity of Pennsylvania, School of Medicine, Phi-
ladelphia, Pennsylvania 19104, USA.
- JOHN B. SCHENKMAN
Department of Pharmacology, University of Con-
necticut Health Center, Farmington, Connecticut
06032, USA.
- HEINZ SCHLEYER
Harrison Department of Surgical Research, Uni-
versity of Pennsylvania, School of Medicine, Phi-
ladelphia, Pennsylvania 19104, USA.
- STEPHEN G. SLIGAR
Department of Molecular Biochemistry and Bio-
physics, Yale University, New Haven, Connecti-
cut 06510, USA.
- ROBERT SNYDER
Department of Pharmacology, Jefferson Medical
College, Thomas Jefferson University, Philadel-
phia, Pennsylvania 19107, USA.
- HENRY W. STROBEL
Department of Biochemistry and Molecular Bio-
logy, University of Texas, Health Sciences Center,
Houston, Texas, USA.
- WALTER W. WAINIO
Department of Biochemistry, Rutgers, The State
University of New Jersey, Piscataway, New Jersey
08854, USA.
- MICHAEL R. WATERMAN
Department of Biochemistry, The University of
Texas, Health Sciences Center, Dallas, Texas
75235, USA.
- JAMES P. WHITLOCK, JR.
Developmental Biochemistry Section, Laboratory
of Nutrition and Endocrinology, NIAMDD,
NIH, Bethesda, Maryland 20014, USA.
- SUSAN B. WEST
Department of Biochemistry and Drug Metab-
olism, Hoffman-La Roche, Inc., Nutley, New Jer-
sey 07710.
- TOSHIO YAMANO
Department of Biochemistry, Medical School,
Osaka University, 33 Joancho, Kitaku, Osaka,
Japan.

CONTENTS

LIST OF CONTRIBUTORS

xv

INTRODUCTION—A Brief History of Cytochrome P-450

JOHN B. SCHENKMAN, *Farmington, Connecticut, USA*

1

PART ONE

Section A—CYTOCHROME P-450 LINKED MONOOXYGENASE

1. PREPARATION AND PROPERTIES OF MICROSOMAL FRACTIONS

LENNART C. ERIKSSON, JOSEPH W. DEPIERRE and GUSTAV DALLNER, *Stockholm, Sweden*

9

- 1. Introduction 9
- 2. Aims of subcellular fractionation 9
- 3. Preparation of total microsomes from rat liver 10
- 4. Preparation of rough and smooth microsomes from liver 22
- 5. Further subfractionation of liver microsomes 28
- 6. Preparation of microsomes from other tissues 35
- 7. Conclusion 39
- References 39

2. ISOLATION AND COMPARISON OF ENDOPLASMIC RETICULUM MEMBRANES AND THEIR MIXED FUNCTION OXIDASE ACTIVITIES FROM MAMMALIAN EXTRAHEPATIC TISSUES

M. DANNY BURKE and STEN ORRENIUS, *Aberdeen, Scotland and Stockholm, Sweden*

47

- 1. Introduction 47
- 2. Lung 47
- 3. Intestine 61
- 4. Kidney 73
- 5. Steroidogenic tissues 79
- 6. Skin 87
- 7. Blood 89
- 8. Miscellaneous tissues 90
- 9. Concluding remarks 90
- References 91

3. CHARACTERISTICS AND DIFFERENCES IN THE HEPATIC MIXED FUNCTION OXIDASES OF DIFFERENT SPECIES

RYUICHI KATO, *Tokyo, Japan*

99

- 1. Introduction 99
- 2. Species differences in *in vivo* metabolism with known substrates of hepatic mixed function oxidases 99
- 3. Mixed function oxidases in hepatic microsomes from various animal species 102
- 4. *In vitro* stability of mixed function oxidase systems from various animal species 115
- 5. Species differences in pre- and post-natal development of mixed function oxidases 117
- 6. Species differences in the inhibition and stimulation of microsomal mixed function oxidases 118
- 7. Species differences in the induction of microsomal mixed function oxidases 122
- 8. Mechanism of species differences in microsomal mixed function oxidases 128
- 9. Species differences in the alterations of microsomal mixed function oxidases under abnormal physiological states 133
- 10. Mixed function oxidases in hepatic microsomes from dog, pig and monkey livers 139
- 11. Mixed function oxidases in microsomes from human liver 141
- 12. Mixed function oxidases in fish and marine animals 145
- 13. Mixed function oxidases in insects 147
- References 149

| | |
|---|-----|
| 4. ENDOGENOUS SUBSTRATES OF MONOOXYGENASES: FATTY ACIDS AND PROSTAGLANDINS | |
| DAVID KUPFER, <i>Shrewsbury, Massachusetts, USA</i> | 157 |
| 1. Fatty acids | 157 |
| 2. Prostaglandins | 167 |
| Conclusion | 182 |
| References | 182 |
| Section B—INDUCTION OF HEPATIC P-450 MONOOXYGENASE | |
| 5. THE MOLECULAR BIOLOGY OF THE INDUCTION OF THE HEPATIC MIXED FUNCTION OXIDASES | |
| EDWARD BRESNICK, <i>Burlington, Vermont, USA</i> | 191 |
| 1. Introduction | 191 |
| 2. Historical aspects | 193 |
| 3. Inhibitor studies | 194 |
| 4. Liver growth, RNA synthesis and induction | 195 |
| 5. Chromatin activation and nuclear protein profiles | 198 |
| 6. Protein synthesis | 200 |
| 7. Receptors and interaction with inducers | 202 |
| 8. Nuclear activation | 203 |
| References | 204 |
| 6. TRANSCRIPTIONAL ASPECTS OF INDUCTION OF HEPATIC CYTOCHROME P-450 | |
| MICHAEL R. WATERMAN, <i>Dallas, Texas, USA</i> | 209 |
| 7. ARYL HYDROCARBON (BENZO(α)PYRENE) HYDROXYLASE INDUCTION IN CELLS IN CULTURE | |
| JAMES P. WHITLOCK, JR. and HARRY V. GELBOIN, <i>Bethesda, Maryland, USA</i> | 213 |
| Introduction | 213 |
| AHH induction by PAH | 214 |
| Decay of AHH activity | 217 |
| AHH induction by temporary inhibition of protein synthesis | 217 |
| AHH induction by cyclic AMP | 218 |
| AHH induction and tyrosine aminotransferase induction | 219 |
| AHH induction in somatic cell hybrids—AHH expression related to human chromosome 2. | 219 |
| Variation in AHH induction in diploid clones | 220 |
| Genetic aspects of AHH in human lymphocytes and monocytes | 222 |
| Comments | 222 |
| Summary | 223 |
| References | 223 |
| 8. CLASSES OF HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE INDUCERS | |
| ROBERT SNYDER and HERBERT REMMER, <i>Philadelphia, PA, USA and Tubingen BRD</i> | 227 |
| 1. Introduction | 227 |
| 2. Early studies on hepatic enzyme induction | 228 |
| 3. Specific classes of enzyme inducers | 229 |
| 4. Characterization of the induction process | 248 |
| 5. Nuclear induction | 253 |
| 6. Studies with purified forms of cytochrome P-450 | 254 |
| 7. Conclusions | 256 |
| References | 257 |

| | |
|---|-----|
| 9. GENETIC DIFFERENCES IN THE INDUCTION OF MONOOXYGENASE ACTIVITIES BY POLYCYCLIC AROMATIC COMPOUNDS | |
| DANIEL W. NEBERT, <i>Bethesda, Maryland, USA</i> | 269 |
| 1. Introduction | 269 |
| 2. The P-450 monooxygenase system | 269 |
| 3. The AHH assay | 270 |
| 4. The Ah locus or "Ah complex" | 275 |
| 5. What is an "inbred" mouse? | 280 |
| 6. Structural genes associated with the Ah locus | 280 |
| 7. How to determine genetic linkage | 281 |
| 8. How to determine the Ah ^b allele phenotype | 283 |
| 9. Evidence for cytosolic receptor as the Ah regulatory gene product | 283 |
| 10. Evidence for temporal control at the Ah locus | 286 |
| 11. Evidence for the Ah locus in the human | 287 |
| 12. Conclusions | 289 |
| References | 289 |

Section C—TURNOVER OF MICROSOMAL ENZYMES

| | |
|--|-----|
| 10. CYTOCHROME P-450 LINKED MIXED FUNCTION OXIDASE: TURNOVER OF MICROSOMAL COMPONENTS AND EFFECTS OF INDUCERS ON THE TURNOVER OF PHOSPHOLIPIDS, PROTEINS AND SPECIFIC ENZYMES | |
| TSUNEO OMURA, <i>Fukuoka, Japan</i> | 295 |
| 1. Turnover of microsomal components and effect of inducers on the turnover | 295 |
| References | 303 |
| 11. LOSS OF MICROSOMAL COMPONENTS IN DRUG-INDUCED LIVER DAMAGE, IN CHOLESTASIS AND AFTER ADMINISTRATION OF CHEMICALS WHICH STIMULATE HEME CATABOLISM | |
| FRANCESCO DE MATTEIS, <i>Carshalton, Surrey</i> | 307 |
| 1. Introduction | 307 |
| 2. Drug-induced loss of microsomal components | 307 |
| 3. Microsomal membrane damage in cholestasis | 325 |
| 4. Loss of cytochrome P-450 caused by starvation and by treatment with iron or with other metals | 327 |
| 5. Summary and conclusions | 332 |
| References | 333 |

PART TWO

Section D—COMPONENTS OF MICROSOMAL ELECTRON TRANSFER

I—NADPH-Cytochrome P-450 Reductase

| | |
|---|-----|
| 12. THE HISTORY, PROPERTIES AND FUNCTION OF NADPH-CYTOCHROME P-450 REDUCTASE | |
| BETTIE SUE SILER MASTERS and RICHARD T. OKITA, <i>Dallas, Texas, USA</i> | 343 |
| 1. Historical background | 343 |
| 2. Purification and properties | 345 |
| 3. Immunochemical properties | 349 |
| 4. Mechanism studies | 350 |
| References | 356 |

13. NADPH CYTOCHROME P-450 REDUCTASE AND ITS ROLE IN THE MIXED FUNCTION OXIDASE REACTION

HENRY W. STROBEL, JOHN DAVID DIGNAM and JAMES R. GUM, *Houston, Texas, USA*

361

| | |
|---|-----|
| 1. Introduction | 361 |
| 2. Isolation and solubilization | 361 |
| 3. Identification of physiological function for reductase | 363 |
| 4. Purification and characterization | 365 |
| 5. Kinetic properties | 366 |
| 6. Oxidation and reduction of the reductase | 367 |
| 7. Physical structure of cytochrome P-450 reductase | 369 |
| 8. Cytochrome P-450 reductase in other tissues | 371 |
| References | 372 |

II—Cytochrome b_5

14. CHEMISTRY AND BIOLOGY OF MAMMALIAN B TYPE CYTOCHROMES

WALTER W. WAINIO, *New Brunswick, New Jersey, USA*

375

| | |
|-----------------------------------|-----|
| 1. Introduction | 375 |
| 2. Terminology | 375 |
| 3. Cellular location | 376 |
| 4. Solubility | 377 |
| 5. Structure and composition | 378 |
| 6. Spectra | 380 |
| 7. Oxidation-reduction potentials | 382 |
| 8. Reactivity | 383 |
| 9. Conclusions | 385 |
| References | 386 |

15. CHEMICAL AND PHYSICAL PROPERTIES OF CYTOCHROME b_5

BUNJI HAGIHARA, E. FURUYA and T. SUGIYAMA, *Osaka, Japan*

389

| | |
|---|-----|
| 1. Introduction | 389 |
| 2. Properties of proteolytically solubilized cytochrome b_5 | 389 |
| 3. Properties of detergent solubilized cytochrome b_5 | 399 |
| References | 402 |

16. CYTOCHROME b_5 AND ITS PHYSIOLOGICAL SIGNIFICANCE

NOZOMU OSHINO, *Osaka, Japan*

407

| | |
|--|-----|
| 1. Introduction | 407 |
| 2. Historical aspect | 407 |
| 3. Distribution of cytochrome b_5 | 410 |
| 4. Solubilization and purification of cytochrome b_5 | 414 |
| 5. Cytochrome b_5 on microsomal membranes | 418 |
| 6. Biosynthesis and degradation of cytochrome b_5 | 421 |
| 7. Constituents of electron transfer system and its physiological function | 424 |
| 8. Acyl CoA Δ^9 -desaturation enzyme system | 430 |
| References | 440 |

17. CYTOCHROME P-450—IV. STABILITY OF CYTOCHROME P-450 AND CONVERSION TO CYTOCHROME P-420: ISOLATION AND PROPERTIES OF CYTOCHROME P-420

TOSHIO YAMANO and YOSHIYUKI ICHIKAWA, *Osaka, Japan*

449

| | |
|---|-----|
| Introduction | 449 |
| Conversion of cytochrome P-450 to cytochrome P-420 in liver microsomes | 452 |
| Reversibility of cytochrome P-420 and P ₁ -420 to cytochrome P-450 and P ₁ -450 (P-448) | 458 |
| Stability of cytochrome P-450 to lipid peroxidation | 464 |
| Stability of cytochrome P-450 at low temperature or when lyophilized | 464 |
| Destruction of cytochrome P-450 by chemical agents | 465 |

| | |
|--|-----|
| Production of cytochrome P-420 during isolation of cytochrome P-450: properties of cytochrome P-420 and prevention of its production | 465 |
| References | 466 |
| 18. EFFECT OF DETERGENTS ON THE MIXED FUNCTION OXIDASE AND OTHER MICROSOMAL ENZYMES | |
| HELMUT DENK, <i>Vienna, Austria</i> | 469 |
| Introduction | 469 |
| Physicochemical characteristics of detergents | 469 |
| Interaction of detergents with biological membranes and their constituents | 474 |
| Interaction of detergents with microsomal mixed function oxidase | 476 |
| Interaction of detergents with enzymes related to microsomal mixed function oxidase | 487 |
| Interaction of detergents with other microsomal enzymes | 489 |
| General conclusion | 491 |
| References | 491 |
| 19. ISOLATION AND PURIFICATION OF CYTOCHROME P-450, AND THE EXISTENCE OF MULTIPLE FORMS | |
| F. PETER GUENGERICH, <i>Nashville, Tennessee, USA</i> | 497 |
| 1. Introduction | 497 |
| 2. Purification of hepatic cytochrome P-450 | 497 |
| 3. The existence of multiple forms of hepatic cytochrome P-450 | 506 |
| References | 516 |
| 20. RECONSTITUTED MAMMALIAN MIXED-FUNCTION OXIDASES: REQUIREMENTS, SPECIFICITIES AND OTHER PROPERTIES | |
| ANTHONY Y. H. LU and SUSAN B. WEST, <i>Nutley, New Jersey, USA</i> | 523 |
| Introduction | 523 |
| Reconstituted liver microsomal mixed-function oxidase | 523 |
| Reconstituted adrenal mitochondrial mixed-function oxidase | 531 |
| Reconstituted adrenal microsomal mixed-function oxidase | 533 |
| Reconstituted lung microsomal mixed-function oxidase | 533 |
| Reconstituted kidney microsomal mixed-function oxidase | 534 |
| Reconstituted kidney mitochondrial mixed-function oxidase | 534 |
| Reconstituted corpus luteum mitochondrial mixed-function oxidase | 535 |
| Reconstituted liver tumor microsomal mixed-function oxidase | 535 |
| Substrate specificities of various forms of purified liver microsomal cytochrome P-450 | 536 |
| Comments on multiplicity of cytochrome P-450 and microsomal hydroxylation | 539 |
| References | 540 |
| Section E—MECHANISM OF P-450 MONOOXYGENASE ACTION | |
| I—Models of activity | |
| 21. MECHANISMS OF REACTION OF HEMEPROTEINS WITH OXYGEN AND HYDROGEN PEROXIDE IN THE OXIDATION OF ORGANIC SUBSTRATES | |
| CHARLES E. CASTRO, <i>Riverside, California, USA</i> | 547 |
| 1. Introduction | 547 |
| 2. Catalase | 547 |
| 3. Peroxidase | 553 |
| 4. Cytochrome P-450 | 556 |
| 5. Tryptophan pyrrolase | 559 |
| 6. Hemoglobin and myoglobin | 561 |
| References | 563 |

22. HYDROPEROXIDES AND SUPEROXIDES IN MICROSOMAL OXIDATIONS

PETER J. O'BRIEN, *St John's, Newfoundland, Canada*

567

| | |
|---|-----|
| 1. The reactivity of activated oxygen species | 567 |
| 2. The nature of the activated oxygen involved in the hydroxylation reactions catalyzed by cytochrome P-450 | 568 |
| 3. Peroxidase activity of cytochrome P-450 | 572 |
| 4. The formation of higher oxidation states of cytochrome P-450 | 572 |
| 5. Multiple forms of cytochrome P-450 | 573 |
| 6. Purified liver microsomal cytochrome P-450. | 575 |
| 7. The peroxidase nature of cytochrome P-450 function | 575 |
| 8. A comparison of P-450 and other peroxidases | 578 |
| 9. The oxidation of electron donors by cytochrome P-450 | 579 |
| 10. The oxidation of hydrogen donors by cytochrome P-450 | 579 |
| 11. Lipid peroxidation and singlet oxygen production catalyzed by cytochrome P-450 | 580 |
| 12. Cytochrome P-450 destruction during the hydroperoxide catalyzed reaction | 580 |
| 13. Summary | 581 |
| References | 582 |

II—Operation of the P-450 Monooxygenase

23. SUBSTRATE INTERACTION WITH CYTOCHROME P-450

JOHN B. SCHENKMAN, STEPHEN G. SLIGAR and DOMINICK L. CINTI, *Farmington and New Haven, Connecticut, USA*

587

| | |
|--|-----|
| 1. Background | 587 |
| 2. Cytochrome P-450 and its spectral changes | 588 |
| 3. Heme iron and spin state | 597 |
| 4. Cytochrome P-450 and spin state | 598 |
| 5. Effect of temperature on the spin state of cytochrome P-450 | 600 |
| 6. Thermodynamic model of substrate binding and spin state interconversion | 604 |
| 7. Effect of lipid binding on P-450 spin state | 606 |
| 8. Influence of the membrane on P-450 function | 607 |
| 9. The spin state and redox potential of cytochrome P-450 | 608 |
| References | 611 |

24. THE ROLE OF THE STIMULATION OF NADPH-CYTOCHROME P-450 REDUCTASE ACTIVITY IN HEPATIC, MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY

JORDAN L. HOLTZMAN, *Minneapolis, Minnesota, USA*

617

| | |
|---|-----|
| 1. General considerations | 617 |
| 2. Biochemistry of cytochrome P-450 reductase | 619 |
| 3. Conclusions and speculations | 639 |
| References | 640 |

25. RATE LIMITING STEP IN MICROSOMAL CYTOCHROME P-450-CATALYZED HYDROXYLATIONS

INGEMAR BJÖRKHEM, *Huddinge, Sweden*

645

| | |
|---|-----|
| Association of substrate to oxidized cytochrome P-450 | 646 |
| Reduction of NADPH-cytochrome P-450 reductase with NADPH | 647 |
| Reduction of cytochrome P-450-substrate complex by reduced cytochrome P-450 reductase | 648 |
| Studies on energy of activation | 653 |
| Inhibition studies with deuterated water | 654 |
| Stimulation of microsomal hydroxylations by high ionic strength | 654 |
| Microsomal hydroxylations supported by organic hydroxyperoxides | 655 |
| Addition of oxygen to reduced cytochrome P-450-substrate complex | 655 |
| Reduction of oxygenated reduced cytochrome P-450-substrate complex | 657 |
| Decomposition of oxygenated reduced cytochrome P-450-substrate complex | 659 |
| General conclusions | 663 |
| References | 664 |

| | |
|--|-----|
| 26. KINETICS OF HEPATIC CYTOCHROME P-450-DEPENDENT MONO-OXYGENASE SYSTEMS | |
| J. E. GANDER and G. J. MANNERING, <i>St Paul and Minneapolis, Minnesota, USA</i> | 667 |
| 1. Introduction | 667 |
| 2. Properties of hepatic microsomal membranes | 668 |
| 3. Influence of temperature on kinetic and thermodynamic properties | 672 |
| 4. The rate-limiting step | 678 |
| 5. Steady-state kinetics of the microsomal mono-oxygenase system | 681 |
| 6. A model for cytochrome P-450-dependent drug metabolism | 688 |
| 7. Summary | 692 |
| References | 693 |
| Appendix | 696 |
| 27. STOICHIOMETRY OF THE MIXED FUNCTION OXIDASE | |
| GARTH POWIS and INGELA JANSSON, <i>Rochester, Maryland, USA, and Farmington, Connecticut, USA</i> | 699 |
| 1. Stoichiometry | 699 |
| 2. Electron transfer | 701 |
| 3. Formation of reactive oxygen intermediates | 702 |
| 4. NADH synergism of NADPH supported mixed function oxidase activity | 705 |
| 5. Mechanism of the mixed-function oxidase | 707 |
| 6. Cytochrome P-450 dependent reduction | 708 |
| 7. Conclusion | 709 |
| References | 709 |
| Section F—ACTIVATION AND INHIBITION OF THE P-450 MONO-OXYGENASE | |
| 28. AGENTS ACTIVATING THE LIVER MICROSOMAL MIXED FUNCTION OXIDASE SYSTEM | |
| DOMINICK L. CINTI, <i>Farmington, Connecticut, USA</i> | 717 |
| 1. Introduction | 717 |
| 2. Activating agents | 717 |
| 3. Enhancing factors | 733 |
| References | 735 |
| 29. INHIBITION OF OXIDATIVE DRUG METABOLISM IN MICROSOMES | |
| KARL J. NETTER, <i>Marburg/Lahn, Germany</i> | 741 |
| 1. Introduction | 741 |
| 2. Inhibitors of drug metabolism | 742 |
| 3. Mechanisms of inhibition | 748 |
| 4. Differential inhibitors | 752 |
| 5. Spatial models of cytochrome P-450 | 754 |
| 6. Conclusions | 757 |
| References | 758 |
| 30. INHIBITION OF MIXED-FUNCTION OXIDATIONS BY SUBSTRATES FORMING REDUCED CYTOCHROME P-450 METABOLIC-INTERMEDIATE COMPLEXES | |
| MICHAEL R. FRANKLIN, <i>Salt Lake City, Utah, USA</i> | 763 |
| 1. Introduction | 763 |
| 2. Scope | 763 |
| 3. Terminology | 763 |
| 4. General properties of metabolic-intermediate complexes | 764 |
| 5. Metabolic-intermediate complex-forming compounds | 765 |
| 6. Structure-activity relationship | 769 |
| 7. Nature of the metabolic-intermediate complex | 772 |
| 8. Effects of cytochrome P-450 induction | 776 |

| | |
|--|-----|
| 9. Species variations | 777 |
| 10. Sex variations | 778 |
| 11. Metabolic intermediate complexes in extrahepatic tissues | 778 |
| 12. Metabolic intermediate complex formation <i>in vivo</i> | 779 |
| 13. Inhibition by metabolic intermediate complexes | 779 |
| References | 781 |

Section G—METHODS OF INTEREST

| | |
|---|-----|
| 31. METHODS FOR THE EVALUATION OF HYDROPHOBIC SUBSTRATE BINDING TO CYTOCHROME P-450 | |
| WAYNE L. BACKES and W. J. CANADY, <i>Morgantown, West Virginia, USA</i> | 787 |
| 1. Introduction | 787 |
| 2. Factors influencing the binding of hydrophobic substrates to cytochrome P-450 | 791 |
| 3. Determination and significance of the thermodynamics of binding | 807 |
| 4. Conclusions | 810 |
| References | 811 |
| 32. ANAEROBIC TECHNIQUES FOR SPECTROPHOTOMETRIC STUDIES OF OXIDATIVE ENZYMES WITH LOW OXIDATION-REDUCTION POTENTIALS | |
| DAVID Y. COOPER, MOTT D. CANNON, HEINZ SCHLEYER, BEATRICE G. NOVACK and OTTO ROSENTHAL, <i>Harrison Pennsylvania, Philadelphia, USA</i> | 813 |
| 1. Introduction | 813 |
| 2. Materials and methods | 814 |
| 3. Use of the titration assembly for anaerobic titrations | 827 |
| References | 831 |
| INDEX | 833 |

INTRODUCTION

A BRIEF HISTORY OF CYTOCHROME P-450

JOHN B. SCHENKMAN

Farmington, Connecticut, USA

Hemoproteins seem to hold some fascination for scientists. As a group hemoproteins are one of the more heavily studied biological compounds. Perhaps this is because they are colored and readily observed. Certainly, interest was strengthened by the early observations that cellular pigments hold a key role in respiratory activity and thus in the process of life itself.

Studies on hemoglobins were carried out in the early part of 1800 while studies on tissue pigments (histohaematin) date back to early spectrophotometric analyses of MacMunn in the 1880's up through the early 1900's, when the individuality of the mitochondrial cytochromes was recognized (Keilin, 1966). The microsomes (small bodies), seen as membranous vesicles after disruption of the liver, were isolated by differential centrifugation and were named by Albert Claude (Claude, 1940). Many years passed, however, before these vesicles were shown to be derived from the endoplasmic reticulum (Palade and Siekevitz, 1956).

Early studies on the microsomal fraction revealed the presence of a protoporphyrin containing hemoprotein (Strittmatter and Ball, 1952; Yoshikawa, 1951). The properties of this protein were described and although variously named, cytochrome m (Strittmatter and Ball, 1954) and cytochrome b' (Yoshikawa, 1951), it came to bear the name cytochrome b₅ (Chance and Williams, 1954).

It is of interest to follow some of the threads in the microsomal electron transfer enzyme story. Britton Chance was Professor and Director of the Johnson Foundation at the University of Pennsylvania School of Medicine, when joined by A. M. Pappenheimer, a visitor from New York University. Pappenheimer had described the presence and involvement of cytochrome b₅ in NADH oxidase activity in *Cecropia* silk worm (Pappenheimer and Williams, 1954) while at Harvard. At the Johnson Foundation the kinetics and spectroscopy of cytochrome b₅ in the midgut of *Cecropia* were described (Chance and Pappenheimer, 1954). Chance observed that the hemoprotein was the same as that found in rat liver microsomes and proceeded to study the kinetics of cytochrome b₅ in rat liver microsomes (Chance and Williams, 1954). Shortly thereafter David Garfinkel, then a postdoctoral fellow at the Johnson Foundation, reported on the properties of cytochrome b₅ isolated from rabbit liver microsomes. In his note (Garfinkel, 1956), he stated that although 50-90% of the cytochrome b₅ was solubilized from the microsomes, the sedimented microsomal pellet contained much of the red color of the original microsomes. Contemporary with Garfinkel at the Johnson Foundation at that time were Martin Klingenberg, a Visiting Scientist from the University of Marburg, Germany, Ryo Sato, a Visiting Professor from Osaka University Institute for Protein Research, and Ronald W. Estabrook a Research Associate.

In the initial studies on solubilization of cytochrome b₅, by Strittmatter and Ball (1952), 1% deoxycholate was used. Microsomal pellets after this treatment were colorless, and from the pyridine hemochrome yield of 1.45 nmoles hemes per milligram microsomal proteins, both cytochrome P-450 (P-420) and cytochrome b₅ must have been solubilized. Of interest was their observation that "equilibrium of a reduced solution with carbon monoxide did not cause a shift of the absorption peaks". Had such a shift been observed then, cytochrome P-450 would have been reported six years earlier than it was. From the elevated pyridine hemochrome levels, it is clear that both hemoproteins were removed

from the microsomes and were present in the extract. Similarly the lack of follow-up of the red pigment remaining in microsomes after up to 90% of the cytochrome b_5 was removed by lipase (Garfinkel, 1956) delayed discovery of cytochrome P-450.

Recognition of the presence of the carbon monoxide binding pigment was attributed to G. R. Williams by Klingenberg (1958) who reported that when the ratio of pyridine hemochromogen to cytochrome b_5 was determined for liver microsomes, a value of 2.15 was obtained, i.e., there was 1.15 nanomoles of excess protohemin. In this paper is the first published spectra and report of a carbon monoxide binding pigment in the microsomes. It was obtained on addition of carbon monoxide to microsomes reduced with either NADH or dithionite ($\text{Na}_2\text{S}_2\text{O}_4$).

In his study, Klingenberg (1958) pointed out that carbon monoxide addition compound is not stable to 2% cholate or 1% deoxycholate, which would explain why Strittmatter and Ball (1952) did not observe the pigment when they gassed the reduced deoxycholate extracts of microsomes with carbon monoxide. As was shown later (Omura and Sato, 1962; 1964b) reduced cytochrome P-420 is destroyed by oxygen, i.e., by aeration when bubbling with carbon monoxide after reduction. If the solution had been saturated with carbon monoxide first and then reduced with diethionite, perhaps cytochrome P-420 would have been seen. Less than half a year later, Garfinkel (1958) also reported on the pigment, suggesting on the basis of the binding of carbon monoxide and cyanide, that it contained a metal ion, but because the pigment had no alpha or beta peaks and showed no photodissociation of the CO complex, that it was probably not an iron hemoprotein.

Ryo Sato returned to Japan where he was studying, among other things, solubilization of the liver microsomal-xenobiotic hydroxylase. With Tsuneo Omura, Sato began investigating the carbon monoxide binding pigment in 1960 (Sato and Omura, 1978), and by 1962 had obtained evidence that the pigment was a protoheme cytochrome (Omura and Sato, 1962). In that report the pigment was, "provisionally called cytochrome P-450, a new cytochrome of unusual properties". Omura and Sato began attempts to fractionate and solubilize the microsomal hemoproteins, and concluded cytochrome b_5 and cytochrome P-450 together account for the total microsomal heme content (Omura and Sato, 1963). However, it wasn't until 1968, that successful separation and solubilization of cytochrome P-450 was achieved (Lu *et al.*, 1968).

Reports from several laboratories rapidly confirmed earlier observations by Sladek and Mannering (1966) that 3-methylcholanthrene induces a new form of cytochrome P-450. Suggestions soon appeared that many isozymes of the hemoprotein exist (Welton and Aust, 1974; Welton *et al.*, 1975; Haugen *et al.*, 1975; Thomas *et al.*, 1976).

Like Klingenberg (1958), Omura and Sato (1964a) were unable to obtain photodissociation of the CO complex of cytochrome P-450. The earliest measurement of photodissociation was of the dithionite reduced CO complex of clarified cytochrome P-450 (Omura *et al.*, 1965), in a collaboration with Q. Gibson at the Johnson Foundation, where photodissociation was obtained. It was not clear whether this was with the liver microsomal or the adrenal cortical mitochondrial cytochrome P-450 (11- β -hydroxylase), since in that report several systems were studied.

In 1964 Omura joined Estabrook, Rosenthal and Cooper at the Johnson Foundation and the Harrison Department of Surgical Research of the University of Pennsylvania (Cooper, 1973). Cooper had been studying the adrenal cortical microsomal steroid hydroxylase and was having difficulty in obtaining a good stoichiometry for the reaction. He joined forces with Ronald W. Estabrook then an Assistant Professor at the Johnson Foundation for Medical Physics, who had just developed a new sensitive fluorimetric assay for pyridine nucleotides. This was the first step of a successful collaboration, and answered the question of the stoichiometry of the C_{21} steroid hydroxylase (Cooper *et al.*, 1963). By 1963 their collaboration led to testing the light reversibility of the carbon monoxide inhibition of C_{21} -hydroxylation of 17-hydroxy progesterone by adrenocortical microsomes (Estabrook *et al.*, 1963). Together they showed a maximal degree of reversibility by light of 450 nm of the carbon monoxide inhibition of cortexolone formation,

and concluded, "these results support the hypothesis that the 450 mu CO compound observed spectrophotometrically functions in oxygen activation for the hydroxylase reaction". The photochemical action spectrum first generated by Estabrook *et al.* (1963) was obtained from carbon monoxide inhibited adrenal cortex microsomes. Later, similar photochemical action spectra were obtained with liver microsomes for codeine metabolism (Cooper *et al.*, 1965a).

In December of 1964 I joined the laboratory of Ronald Estabrook at the Johnson Foundation, then the Department of Biophysics and Physical Biochemistry of the University of Pennsylvania School of Medicine. My stay there overlapped by about a year that of Omura, who subsequently left to work with Philip Siekevitz at the Rockefeller Institute. Estabrook and I examined the effect of drug substrates on the EPR and UV-visible spectrophotometric properties of the mixed function oxidase. Shakunthala Narasimhulu, a Research Associate with David Y. Cooper for a few years, had been studying the properties of the adrenal cortical microsomal mixed function oxidase. She observed (Narasimhulu *et al.*, 1965; Cooper *et al.*, 1965b) that steroid substrate addition caused a change in the microsomal difference spectrum which was substrate dependent. These spectral changes were characterized by a drop in absorbance at 420 nm and a peak at 390 nm. An important observation was also made that the substrate, when added, enhances electron flow from TPNH to cytochrome P-450 in the adrenal microsomes (Narasimhulu *et al.*, 1965). While examining the effect of drug substrates of the monooxygenase in liver microsomes, we observed similar spectral changes. At Estabrook's invitation, Henry Sasame and James R. Gillette visited the Johnson Foundation for a brain session of the meaning of the spectral changes. Also present was Herbert Remmer, then a visiting Professor from Tübingen, Germany. Working late into the night a consensus conclusion was reached that the substrate induced spectral changes were due to formation of an enzyme-substrate complex; a report was sent to *Molecular Pharmacology*. In that short communication, (Remmer *et al.*, 1966) all bases were touched: Substrates were suggested as substituting for a ligand of the heme, and the two types of spectral changes seen were considered as two types of conformational change, perhaps by ligand binding to opposite sides of the heme. An alternative suggestion similar to that of Narasimhulu *et al.*, 1965 was also considered, involving conversion of an oxygenated form of cytochrome P-450 to an oxidized form (an analogy with peroxidases). Similar observations were made by Imai and Sato (1966) of spectral changes on addition of substrates to rabbit liver microsomes. The spectral changes were later named Type I and Type II spectral changes (Schenkman *et al.*, 1967).

At about the same time cytochrome P-450 was also generating excitement on the international scene. In Germany, Remmer had shown barbiturates to induce the microsomal drug oxidase (Remmer, 1959). In Sweden, Ernster's group showed induction to be related to elevation of the microsomal content of cytochrome P-450 (Orrenius *et al.*, 1965). In Australia, Appleby had isolated a soluble form of cytochrome P-450 from *Rhizobium japonicum* (Appleby, 1967). In the U.S., cytochrome P-450 was shown to resemble a low spin hemoprotein by electron spin resonance (ESR) spectroscopy (Hashimoto *et al.*, 1962; Mason *et al.*, 1965). With *Pseudomonas* cytochrome P-450 a Type I substrate (camphor) was shown to decrease the amount of low spin cytochrome ESR signal (Gunsalus, 1968). In Japan (Mitani and Horie, 1969) and in the U.S. (Whysner *et al.*, 1969) investigators showed the substrate induced type I spectral change was related to spin state changes of the cytochrome.

Today the excitement in research on cytochrome P-450 shows no signs of abating. Many more researchers in many other countries, too numerous to mention here, have joined in the study on the properties of the cytochrome. From early pharmacological studies on drug metabolism *in vivo*, the field moved to biochemical studies on the enzyme kinetics, through enzyme purification and system reconstitution to current investigations on the thermodynamics of P-450. One can easily see there are many fruitful years of research left on this hemoprotein. As newer techniques are applied to it an even greater understanding of its properties and functions will be obtained.